Abstract
We performed comparative genomic hybridization (CGH) and high-resolution deletion mapping of the long arm of chromosome 2 (2q) in invasive cervical carcinoma (CC). The CGH analyses on 52 CCs identified genetic losses at 2q33–q36, gain of 3q26–q29, and frequent chromosomal amplifications. Characterization of 2q deletions by loss of heterozygosity (LOH) in 60 primary tumors identified two sites of minimal deleted regions at 2q35–q36.1 and 2q36.3–q37.1. To delineate the stage at which these genetic alterations occur in CC progression, we analysed 33 cervical intraepithelial neoplasia (CIN) for LOH. We found that 89% of high-grade (CINII and CINIII) and 40% of low-grade (CINI) CINs exhibited LOH at 2q. To identify the target tumor suppressor gene (TSG), we performed an extensive genetic and epigenetic analyses of a number of candidate genes mapped to the deleted regions. We did not find inactivating mutations in CASP10, BARD1, XRCC5, or PPP1R7 genes mapped to the deleted regions. However, we did find evidence of downregulated gene expression in CFLAR, CASP10 and PPP1R7 in CC cell lines. We also found reactivated gene expression in CC cell lines in vitro after exposure to demethylating and histone deacetylase (HDAC) inhibiting agents. Thus, these data identify frequent chromosomal amplifications in CC, and sites of TSGs at 2q35–q36.1 and 2q36.3–q37.1 that are critical in CC development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS . (1997). Science, 277, 965–968.
NIH Consensus Statement. (1996). Cervical Cancer, Vol. 14. NIH: MD, pp. 1–38.
Chatterjee A, Pulido HA, Koul S, Beleño N, Perilla A, Posso H, Manusukhani M and Murty VVVS . (2001). Cancer Res., 61, 2119–2123.
Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ and Moch H . (1999). Cancer Res., 59, 3475–3479.
Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE, Ried T and Nussenzweig A . (2000). Nature, 404, 510–514.
Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SM, Wang L, Bullrich F, Fritz LC, Trapani JA, Tomaselli KJ, Litwack G and Alnemri ES . (1996). Proc. Natl. Acad. Sci. USA, 93, 7464–7469.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.
Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, Auer G and Ried T . (1997). Genes Chromosomes Cancer, 19, 233–240.
Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G and Ried T . (1996). Proc. Natl. Acad. Sci. USA, 93, 479–484.
Hidalgo A, Schewe C, Petersen S, Salcedo M, Gariglio P, Schluns K, Dietel M and Petersen I . (2000). Eur. J. Cancer, 36, 542–548.
Hu N, Roth MJ, Polymeropolous M, Tang ZZ, Emmert-Buck MR, Wang QH, Goldstein AM, Feng SS, Dawsey SM, Ding T, Zhuang ZP, Han XY, Ried T, Giffen C and Taylor PR . (2000). Genes Chromosomes Cancer, 27, 217–228.
Kersemaekers AM, van de Vijver MJ, Kenter GG and Fleuren GJ . (1999). Genes Chromosomes Cancer, 26, 346–354.
Kinoshita M, Kumar S, Mizoguchi A, Ide C, Kinoshita A, Haraguchi T, Hiraoka Y and Noda M . (1997). Genes Dev., 11, 1535–1547.
Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, Bryndorf T, Kryger-Baggesen N, Christensen L, Engelholm SA and Philip J . (1999). Genes Chromosomes Cancer, 24, 144–150.
Kubbutat MHG and Vousden KH . (1996). Semin. Virol., 7, 295–304.
Kurzrock R, Ku S and Talpaz M . (1995). Cancer, 75, 584–590.
Lazo PA . (1999). Br. J. Cancer, 80, 2008–2018.
Lim DS, Vogel H, Willerford DM, Sands AT, Platt KA and Hasty P . (2000). Mol. Cell. Biol., 20, 3772–3780.
Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK and Shen CY . (2000). Oncogene, 19, 2739–2744.
Mitra AB, Murty VVVS, Pratap M, Sodhani P and Chaganti RSK . (1994). Cancer Res., 54, 637–639.
Mitra AB, Murty VVVS, Singh V, Li RG, Pratap M, Sodhani P, Luthra UK and Chaganti RSK . (1995). J. Natl. Cancer Inst., 87, 742–745.
Munger K, Scheffner M, Huibregtse JM and Howley PM . (1992). Cancer Surv., 12, 197–217.
Murthy NS, Sehgal A, Satyanarayana L, Das DK, Singh V, Das BC, Gupta MM, Mitra AB and Luthra UK . (1990). Br. J. Cancer, 61, 732–736.
Ostor AG . (1993). Int. J. Gynecol. Pathol., 12, 186–192.
Otsuka T, Kohno T, Mori M, Noguchi M, Hirohashi S and Yokota J . (1996). Genes Chromosomes Cancer, 16, 113–119.
Pulido HA, Fakruddin MJ, Chatterjee A, Esplin ED, Beleño N, Martínez G, Posso H, Evans GA and Murty VVVS . (2000). Cancer Res., 60, 6677–6682.
Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H and Huettner PC . (1998). Genes Chromosomes Cancer, 22, 57–65.
Ransom DT, Barnett TC, Bot J, de Boer B, Metcalf C, Davidson JA and Turbett GR . (1998). Head Neck, 20, 404–410.
Renouf S, Beullens M, Wera S, Van Eynde A, Sikela J, Stalmans W and Bollen M . (1995). FEBS Lett., 375, 75–78.
Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC and Chaganti RS . (1998). Blood, 92, 234–240.
Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW and Vogelstein B . (2001). Science, 294, 1343–1346.
Schwab M . (1999). Semin. Cancer Biol., 9, 319–325.
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godgrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW . (1999). Nat. Genet., 21, 99–102.
Shu HB, Halpin DR and Goeddel DV . (1997). Immunity, 6, 751–763.
Singh B, Gogineni SK, Sacks PG, Shaha AR, Shah JP, Stoffel A and Rao PH . (2001). Cancer Res., 61, 4506–4513.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C and Lowe SW . (2001). Nature, 409, 207–211.
Srivastava M and Pollard HB . (1999). FASEB J., 13, 1911–1922.
Taccioli GE, Gottlieb TM, Blunt T, Priestley A, Demengeot J, Mizuta R, Lehmann AR, Alt FW, Jackson SP and Jeggo PA . (1994). Science, 265, 1442–1445.
Takita J, Yang HW, Chen YY, Hanada R, Yamamoto K, Teitz T, Kidd V and Hayashi Y . (2001). Oncogene, 20, 4424–4432.
Teitz T, Lahti JM and Kidd VJ . (2001). J. Mol. Med., 79, 428–436.
Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ . (2000). Nat. Med., 6, 529–535.
Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R and Bowcock AM . (1998). Hum. Mol. Genet., 7, 195–202.
Tung WS, Shevlin DW, Kaleem Z, Tribune DJ, Wells Jr SA and Goodfellow PJ . (1997). Genes Chromosomes Cancer, 19, 43–51.
Tycko B . (2000). J. Clin. Invest., 105, 401–407.
Uejima H, Shinohara T, Nakayama Y, Kugoh H and Oshimura M . (1998). Mol. Carcinogen, 22, 34–45.
Umayahara K, Numa R, Suehiro Y, Sakata A, Nawata S, Ogata H, Suminami Y, Sakamoto M, Sasaki K and Kato H . (2002). Genes Chromosomes Cancer, 33, 98–102.
Vincenz C and Dixit VM . (1997). J. Biol. Chem., 272, 6578–6583.
Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE and Lenardo MJ . (1999). Cell, 98, 47–58.
Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM and Baer R . (1996). Nat. Genet., 14, 430–440.
Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C and Otterson GA . (2001). Oncogene, 20, 7787–7796.
zur Hausen H and Rosl F . (1994). Cold Spring Harb. Symp. Quant Biol., 9, 623–628.
Acknowledgements
We thank Dr Thomas C Wright Jr for reviewing the histology and for critical reading of the manuscript. We also thank the gynecologists at INC, Santa Fe de Bogota, Colombia, for specimen collection. This work was supported by the Elaine B Lesser Fund and the Herbert Irving Comprehensive Cancer Center, Columbia University to VVVSM and a grant (2101-04-021-99) from Colciencias, Colombia, to HAP.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Narayan, G., Pulido, H., Koul, S. et al. Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression. Oncogene 22, 3489–3499 (2003). https://doi.org/10.1038/sj.onc.1206432
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206432
Keywords
This article is cited by
-
Characterization of genomic changes in the cervical pre-cancerous lesions and tumors induced by different types of human papillomaviruses
VirusDisease (2016)
-
Sds22/PP1 links epithelial integrity and tumor suppression via regulation of myosin II and JNK signaling
Oncogene (2011)
-
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Nature Reviews Cancer (2010)
-
Array comparative genomic hybridization analysis of olfactory neuroblastoma
Modern Pathology (2008)
-
Cancer and forensic microsatellites
Forensic Science, Medicine, and Pathology (2008)